AAAa Jennifer Adgey

Aa Jennifer Adgey

*This is an algorithmically generated author record based on publicly available information.

Current Organizations / Institutes

The organizations/institutes from the scholar's latest article

Previous Organizations / Institutes

The organizations / institutes from the scholar's other articles in the past ten years


Aa Jennifer Adgey has a total of 60 co-authors. Here are the top co-authors by number of shared publications:


Latest Publications

  • Open Access

    Improving the Diagnosis of Culprit Left Circumflex Occlusion With Acute Myocardial Infarction in Patients With a Nondiagnostic 12‐Lead ECG at Presentation: A Retrospective Cohort Study

    by Michael J. Daly, Peter J. Scott, Mark T. Harbinson, Jennifer A. Adgey

    Background: Left circumflex culprit is often missed by the standard 12‐lead ECG . Extended lead systems (body surface potential map [ BSPM ]) should improve the diagnosis of culprit left circumflex stenosis with myocardial infarction. Methods and Results: Retrospective analysis of a hospital research registry (August 2000–August 2010) comprising consecutive patients with (1) ischemic‐type chest pain at rest; (2) 12‐lead ECG and 80‐lead BSPM at first medical contact; and (3) cardiac troponin‐T 12 hours after symptom onset and/or creatine kinase MB fraction, were undertaken. Enrolled in the cohort were patients with culprit left circumflex stenosis (thrombolysis in myocardial infarction flow grade 0/1) at angiography. Acute myocardial infarction AMI was defined as cardiac troponin‐T ≥0.1 μg/L and/or creatine kinase MB fraction >2 upper limits of normal. Enrolled were 482 patients: 168 had exclusion criteria. Of the remaining 314 (age 64±11 years; 62% male), 254 (81%) had AMI : of these, 231 had BSPM STE —sensitivity 0.91, specificity 0.72, positive predictive value 0.93, negative predictive value 0.65, and c‐statistic 0.803 for AMI ( P <0.001). Of those with BSPM STE and AMI (n=231), STE was most frequently detected in the posterior (n=111, 48%), lateral (n=53, 23%), inferior (n=39, 17%), and right ventricular (n=21, 9%) territories. Conclusions: Among patients with 12‐lead ECG non‐ST‐segment–elevation myocardial infarction and culprit left circumflex stenosis, initial BSPM identifies ST‐segment elevation beyond the territory of the 12‐lead ECG . Greater use of the BSPM may result in earlier identification of AMI , which may lead to more rapid reperfusion.


  • Epicardial potentials computed from the body surface potential map using inverse electrocardiography and an individualised torso model improve sensitivity for acute myocardial infarction diagnosis

    by Michael J Daly, Dewar D Finlay, Daniel Guldenring, Raymond R Bond, Aaron J McCann, Peter J Scott, Jennifer A Adgey, Mark T Harbinson

    Epicardial potentials (EPs) derived from the body surface potential map (BSPM) improve acute myocardial infarction (AMI) diagnosis. In this study, we compared EPs derived from the 80-lead BSPM using a standard thoracic volume conductor model (TVCM) with those derived using a patient-specific torso model (PSTM) based on body mass index (BMI). Consecutive patients presenting to both the emergency department and pre-hospital coronary care unit between August 2009 and August 2011 with acute ischaemic-type chest pain at rest were enrolled. At first medical contact, 12-lead electrocardiograms and BSPMs were recorded. The BMI for each patient was calculated. Cardiac troponin T (cTnT) was sampled 12 hours after symptom onset. Patients were excluded from analysis if they had any ECG confounders to interpretation of the ST-segment. A cardiologist assessed the 12-lead ECG for ST-segment elevation myocardial infarction by Minnesota criteria and the BSPM. BSPM ST-elevation (STE) was ⩾0.2 mV in anterior, ⩾0.1 mV in lateral, inferior, right ventricular or high right anterior and ⩾0.05 mV in posterior territories. To derive EPs, the BSPM data were interpolated to yield values at 352 nodes of a Dalhousie torso. Using an inverse solution based on the boundary element method, EPs at 98 cardiac nodes positioned within a standard TVCM were derived. The TVCM was then scaled to produce a PSTM using a model developed from computed tomography in 48 patients of varying BMIs, and EPs were recalculated. EPs >0.3 mV defined STE. A cardiologist blinded to both the 12-lead ECG and BSPM interpreted the EP map. AMI was defined as cTnT ⩾0.1 µg/L. Enrolled were 400 patients (age 62 ± 13 years; 57% male); 80 patients had exclusion criteria. Of the remaining 320 patients, the BMI was an average of 27.8 ± 5.6 kg/m2. Of these, 180 (56%) had AMI. Overall, 132 had Minnesota STE on ECG (sensitivity 65%, specificity 89%) and 160 had BSPM STE (sensitivity 81%, specificity 90%). EP STE occurred in 165 patients using TVCM (sensitivity 88%, specificity 95%; p < 0.001) and in 206 patients using PSTM (sensitivity 98%, specificity 79%; p < 0.001). Of those with AMI by cTnT and EPs ⩽0.3 mV using TVCM (n = 22), 18 (82%) patients had EPs >0.3 mV when an individualised PSTM was used. Among patients presenting with ischaemic-type chest pain at rest, EPs derived from BSPM using a novel PSTM significantly improve sensitivity for AMI diagnosis.


  • Open Access

    The REFLO-STEMI trial comparing intracoronary adenosine, sodium nitroprusside and standard therapy for the attenuation of infarct size and microvascular obstruction during primary percutaneous coronary intervention: study protocol for a randomised controlled trial

    by Sheraz A Nazir, Jamal N Khan, Islam Z Mahmoud, John P Greenwood, Daniel J Blackman, Vijay Kunadian, Martin Been, Keith R Abrams, Robert Wilcox, Aa Jennifer Adgey, et al.

    Microvascular obstruction (MVO) secondary to ischaemic-reperfusion injury is an important but underappreciated determinant of short- and longer-term outcome following percutaneous coronary intervention (PCI) treatment of ST-elevation myocardial infarction (STEMI). Several small studies have demonstrated a reduction in the degree of MVO utilising a variety of vasoactive agents, with adenosine and sodium nitroprusside (SNP) being most evaluated. However, the evidence base remains weak as the trials have had variable endpoints, differing drug doses and delivery. As such, the results regarding benefit are conflicting. The REperfusion Facilitated by LOcal adjunctive therapy in STEMI (REFLO-STEMI) trial is a multicentre, prospective, randomised, controlled, open label, study with blinded endpoint analysis: Patients presenting within 6 h of onset of STEMI and undergoing planned primary PCI (P-PCI) with TIMI 0/1 flow in the infarct-related artery (IRA) and no significant bystander coronary artery disease on angiography, are randomised into one of three groups: PCI with adjunctive pharmacotherapy (intracoronary adenosine or SNP) or control (standard PCI). All receive Bivalirudin anticoagulation and thrombus aspiration. The primary outcome is infarct size (IS) (determined as a percentage of total left ventricular mass) measured by cardiac magnetic resonance imaging (CMRI) undertaken at 48 to 72 h post P-PCI. Secondary outcome measures include MVO (hypoenhancement within infarct core) on CMRI, angiographic markers of microvascular perfusion and MACE during 1-month follow-up. The study aims to recruit 240 patients (powered at 80% to detect a 5% absolute reduction in IS). The REFLO-STEMI study has been designed to address the weaknesses of previous trials, which have collectively failed to demonstrate whether adjunctive pharmacotherapy with adenosine and/or SNP can reduce measures of myocardial injury (infarct size and MVO) and improve clinical outcome, despite good basic evidence that they have the potential to attenuate this process. The REFLO-STEMI study will be the most scientifically robust trial to date evaluating whether adjunctive therapy (intracoronary adenosine or SNP following thrombus aspiration) reduces CMRI measured IS and MVO in patients undergoing P-PCI within 6 h of onset of STEMI. Trial registered 20th November 2012: ClinicalTrials.gov Identifier NCT01747174 .


  • Open Access

    042 EPICARDIAL POTENTIALS DERIVED FROM THE BODY SURFACE POTENTIAL MAP USING INVERSE ELECTROCARDIOGRAPHY IMPROVE DIAGNOSIS OF ACUTE MYOCARDIAL INFARCTION: A PROSPECTIVE STUDY

    by M J Daly, D D Finlay, D Guldenring, P J Scott, A A J Adgey, M T Harbinson

    Background Epicardial potentials (EP) derived from body surface potentials using a thoracic volume conductor model (TVCM) improve acute myocardial infarction (AMI) diagnosis. In this study, we compared EP derived from the 80-lead body surface potential map (BSPM) using a TVCM developed from CT imaging with other electrocardiographic techniques in AMI diagnosis. Methods In this prospective study, consecutive patients presenting to both the ED and pre-hospital coronary care unit between August 2009 and August 2011 with acute ischaemic-type chest pain at rest were enrolled. At first medical contact a 12-lead electrocardiogram (ECG) and BSPM were recorded. Cardiac troponin-T (cTnT) was sampled 12 h after symptom onset. AMI was diagnosed when cTnT ≥0.1 µg/l. Patients were excluded from analysis if they had bundle branch block, permanent pacemaker, left ventricular hypertrophy by voltage criteria or concomitant digitalis therapy. A cardiologist assessed the 12-lead ECG for STEMI by Minnesota criteria and the BSPM. BSPM ST-elevation (STE) was ≥0.2 mV in anterior, ≥0.1 mV in lateral, inferior, right ventricular (RV) or high right anterior and ≥0.05 mV in posterior territories indicating AMI. To derive EP, the 80-lead BSPM data were interpolated (Laplacian method) to yield values at 352-nodes of a Dalhouse torso. Using an inverse solution based on the boundary element method employing Tikhonov regularisation, EP at 98 cardiac nodes positioned within a standard TVCM were estimated. EP ≥0.3 mV defined STE. A cardiologist blinded to both the 12-lead ECG and BSPM interpreted the EP map. Results Enrolled were 400 patients (age 62±13 years; 57% male): 80 patients had exclusion criteria. Of the remaining 320 patients, 180 (56%) had AMI. Of these 180 patients, 117 had STEMI by Minnesota criteria (sensitivity 65%, specificity 89%) and 146 had BSPM STE (sensitivity 81%, specificity 90%). EP STE occurred in 158 patients (sensitivity 88%, specificity 95%, p<0.001). Of those with non-STEMI by Minnesota criteria on 12-lead ECG and AMI (n=63), 29 (46%) patients had STE detected by BSPM with a further 12 (19%) patients having STE detected only using EP derived from the BSPM using a TVCM. Overall, 41 (65%) patients with both a non-diagnostic 12-lead ECG at presentation and AMI had STE detected only by BSPM or derived EP. In 32/41 (78%) patients, STE was detected in the posterior or RV territories. All 41 patients had AMI diagnosed by EP. Conclusions Among those with an initial non-diagnostic 12-lead ECG, EP derived from BSPM using a TVCM significantly improves AMI diagnosis.

  • Open Access

    Detection of acute coronary occlusion in patients with acute coronary syndromes presenting with isolated ST-segment depression

    by Mj Daly, Dd Finlay, D Guldenring, Cd Nugent, A Tomlin, B Smith, Aaj Adgey, Mt Harbinson

    Objectives: This study sought to determine whether 80-lead body surface potential mapping (BSPM) would improve detection of acute myocardial infarction (AMI) and occluded culprit artery in patients presenting with ST-segment depression (STD) only on 12-lead ECG. Background: In patients with acute coronary syndromes (ACS), the standard 12-lead ECG has limited sensitivity (50–60%) for AMI. Methods: Consecutive patients presenting pre- and in-hospital between 2000 and 2006 with acute ischaemic-type chest pain and an initial 12-lead ECG with STD only of ≥ 0.05 mV in two or more contiguous leads were analysed. Flow in the culprit artery at angiography was graded using the TIMI flow grade (TFG) criteria. Results: Enrolled were 410 patients: of these, 240 (59%) had an occluded culprit artery (TFG 0/1) with AMI, 80 (19%) had a patent culprit artery (TFG 2/3) with AMI, 67 (16%) had TFG 2/3 with cardiac troponin T (cTnT) p = 0.003). Conclusion: Among 410 ACS patients presenting with only STD, BSPM identifies STE beyond the territory of the 12-lead ECG with sensitivity 91% and specificity 72% for diagnosis of occluded culprit artery with AMI.


  • An Innovative Piezoelectric-Based Method for Measuring Pulse Wave Velocity in Patients With Hypertension

    by John C. Murphy, Katherine Morrison, James McLaughlin, Ganesh Manoharan, Aa Jennifer Adgey

    J Clin Hypertens (Greenwich). 2011;13:497–505.©2011 Wiley Periodicals, Inc.


  • Open Access

    Novel biomarkers in early diagnosis of acute myocardial infarction compared with cardiac troponin T

    by Conor J. McCann, Ben M. Glover, Ian B.A. Menown, Michael J. Moore, Jane McEneny, Colum G. Owens, Bernie Smith, Peter C. Sharpe, Ian S. Young, Jennifer A. Adgey

    To evaluate the role of novel biomarkers in early detection of acute myocardial infarction (MI) in patients admitted with acute chest pain. A prospective study of 664 patients presenting to two coronary care units with chest pain was conducted over 3 years from 2003. Patients were assessed on admission: clinical characteristics, ECG (electrocardiogram), renal function, cardiac troponin T (cTnT), heart fatty acid binding protein (H-FABP), glycogen phosphorylase-BB, NT-pro-brain natriuretic peptide, D-dimer, hsCRP (high sensitivity C-reactive protein), myeloperoxidase, matrix metalloproteinase-9, pregnancy associated plasma protein-A, soluble CD40 ligand. A ≥12 h cTnT sample was also obtained. MI was defined as cTnT ≥ 0.03 µg/L. In patients presenting P = 0.043). Specificity of H-FABP was 71%. None of the other biomarkers challenged cTnT. Combined use of H-FABP and cTnT (either one elevated initially) significantly improved the sensitivities of H-FABP or cTnT (85%; P ≤ 0.004). This combined approach also improved the negative predictive value, negative likelihood ratio, and the risk ratio. Assessment of H-FABP within the first 4 h of symptoms is superior to cTnT for detection of MI, and is a useful additional biomarker for patients with acute chest pain.